Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.
نویسندگان
چکیده
منابع مشابه
Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis
Emergence of drug resistant tuberculosis like multi drug resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB) and totally drug resistant tuberculosis (TDR-TB) has created a new challenge to fight against these bad bugs of Mycobacterium tuberculosis. Repurposing and revival of the drugs are the new trends/options to combat these worsen situations of tuberculosis in t...
متن کاملCombined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic review has yet evaluated the efficacy, safety, and tolerability of delamanid and bedaquiline use...
متن کاملProfile of delamanid for the treatment of multidrug-resistant tuberculosis
New approaches to the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) are badly needed. Not only is the success rate of current treatment regimens suboptimal but existing regimens require multiple drugs and lengthy courses and may lead to significant toxicities. The treatment landscape is beginning to shift, however, with the recent approvals of the new TB drug...
متن کاملAcquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
متن کاملVariation in policy and practice of adolescent tuberculosis management in the WHO European Region
in Children. 2nd Edn. WHO/HTM/TB/2014.03. Geneva, World Health Organization, 2014. http://apps.who.int/ medicinedocs/documents/s21535en/s21535en.pdf 6 Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016; 20: 177–186. 7 Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- American journal of respiratory and critical care medicine
دوره 193 3 شماره
صفحات -
تاریخ انتشار 2016